Drug levels in the blood (anti-epileptic drug: Keppra®)

Active ingredient
levetiracetam (Keppra®, UCB Pharma Sector, Belgium)


1 film-coated tablet of Keppra contains: 250 mg / 500 mg / 750 mg or 1,000 mg of levetiracetam.

The additional treatment of partial seizures with or without secondary generalisation in patients with epilepsy.

Application restrictions
Children under 16 years of age, in patients with impaired renal or hepatic function (checking of renal function, dosage adjustment).

Hypersensitivity to pyrrolidone derivatives and pregnancy.

Side effects
Common side effects include asthenia, somnolence; headache, anorexia, diarrhoea, dyspepsia, nausea, amnesia, ataxia, convulsions, depression, dizziness, emotional instability, hostility, insomnia, nervousness, tremors, dizziness, rash, diplopia.

To date, no severe symptoms for single doses of up to 5000 mg. No empirical data for doses of over 5000 mg/day. Treatment of an overdose by means of general measures, such as gastric lavage, inducing vomiting, haemodialysis.

Other properties
Levetiracetam is a readily soluble, membrane-permeable substance and is absorbed rapidly after oral administration. The pharmacokinetic profile of the dose is linear, with slight intra-individual and inter-individual variability.
The mechanism of action is unknown for levetiracetam.

Test material
1 ml of serum (shelf life of the samples: one week at 2-8 °C, with deep-frozen storage required for longer periods)

Therapeutic range
Dose adjustment necessary, depending on the efficacy of and tolerance to the drug

Reference values
Levetiracetam: At doses of 500-3000 mg/day, drugs levels in the blood of 10-100 mg/l are to be expected (Chromesystems GmbH).

To top